


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 15 Sep 2021
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
HSMN NewsFeed - 8 Sep 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
HSMN NewsFeed - 7 Sep 2021
EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline
EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline
HSMN NewsFeed - 2 Sep 2021
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
HSMN NewsFeed - 30 Aug 2021
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA(TM) Platform
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA(TM) Platform
HSMN NewsFeed - 24 Aug 2021
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
HSMN NewsFeed - 17 Aug 2021
Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer
Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer
HSMN NewsFeed - 17 Aug 2021
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
HSMN NewsFeed - 5 Aug 2021
Breckenridge Announces Final Approval of its ANDA for Apixaban Tablets (generic for Eliquis(R))
Breckenridge Announces Final Approval of its ANDA for Apixaban Tablets (generic for Eliquis(R))
HSMN NewsFeed - 5 Aug 2021
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
